Pharmacovigilance Programme of India: A Review

Saurabh Nimesh
Saurabh Nimesh
Surabhi Gupta
Surabhi Gupta Database Software Engineer
Kapil Dev Negi
Kapil Dev Negi
Dr. A.P.J. Abdul Kalam Technical University

Send Message

To: Author

Pharmacovigilance Programme of India: A Review

Article Fingerprint

ReserarchID

PDDTMJ4HV0

Pharmacovigilance Programme of India: A Review Banner

AI TAKEAWAY

Connecting with the Eternal Ground
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
Font Type
Font Size
Font Size
Bedground

Abstract

In India, a proper adverse drug reaction monitoring system was started in 1986 with 12 regional centers. In 1997, India became the member of the World health organization Programme for International Drug watching managed by the Upsala Monitoring Centre, Sweden. At origination, 6 regional centers were created in Mumbai, New Delhi, Kolkata, Lucknow, Pondicherry, and Chandigarh for ADR watching within the country. Promoting safe use of drugs may be a priority of the Indian Pharmacopoeia Commission that functions as the National Coordination Centre for Pharmacovigilance Programme of India. Today, 179 adverse drug reactions monitoring centers presently report adverse events to the National coordinative centre in India.

References

25 Cites in Article
  1. S Nimesh,Prem Parkash,K (2019). A Prospective Observational Study on Assessment of Adverse Drug Reactions in Patients taking First Line Antitubercular Drugs at Tertiary Care Teaching Hospital, Nellore.
  2. S Nimesh,V Ashwlayan (2018). Pharmacovigilance: An Overview.
  3. Nisha Kaushik,Arti Thakkar,K Bangarurajan (2006). COVID-19 and Standardized Vaccines Development: A Brief Review.
  4. U (2017). National Library of Medicine.
  5. S Srivastava (2017). The Complete Cookery Book for Diabetics.
  6. B Mohamed,I Elnagar (2017). Prevalence and Extent of Adverse Drug Reactions in Sudanese Patients in Highly Active Antiretroviral Therapy Regimens.
  7. Z Zhu,B Hofauer,M Wirth,Katrin Hasselbacher,Helmut Frohnhofen,Clemens Heiser (2018). Selective upper airway stimulation in older patients.
  8. S Najafi (2018). Importance of Pharmacovigilance and the Role of Healthcare Professionals.
  9. (2018). Pharmacovigilance Programme of India. Safety of medicines: The journey travelled and the way forward.
  10. Philip Routledge (2018). 150 years of pharmacovigilance.
  11. (2017). Role of Pharmacovigilance Programme of India (PvPI) in Adverse Drug Event Monitoring for medication safety in patient.
  12. Gurumurthy Parthasarathi,A Harugeri,K Undela (2018). Pharmacovigilance Research in India: A Five-Year Literature Review.
  13. M Khan,S Ali,S Alam (2018). Assessment of prescribing trend of drugs at out patient's chest ward of government tertiary care hospital situated in karachi.
  14. Francine Birungi,Stephen Graham,Jeannine Uwimana,Brian Van Wyk (2018). Assessment of the Isoniazid Preventive Therapy Uptake and Associated Characteristics: A Cross-Sectional Study.
  15. Vivekanandan Kalaiselvan,Prasad Thota,Gyanendranath Singh (2016). Pharmacovigilance Programme of India: Recent developments and future perspectives.
  16. K Bester,H Meyer,M Crowther,R Gray (2018). Anaesthesia for paediatric patients: Minimising the risk.
  17. C Krishnamurti (2018). Reprieves before rejection: chloroform for anesthesia.
  18. J West (2018). The Accidental Poison That Founded the Modern FDA. Elixir Sulfanilamide was a breakthrough antibiotic-until it killed more than 100 people.
  19. Knm Singh,H Kanase (2017). Pharmacovigilance Programme of India: The Beginning, Current Status and Recent Progress.
  20. B Panja,S Bhowmick,V Chowrasia,S Bhattacharya,A Chatterjee R N, Sen (2015). A cross-sectional study of adverse drug reactions reporting among doctors of a private medical college in Bihar.
  21. Helen Ndagije,Victoria Nambasa,Elizabeth Namagala,Huldah Nassali,Dan Kajungu,Gordon Sematiko,Sten Olsson,Shanthi Pal (2015). Targeted Spontaneous Reporting of Suspected Renal Toxicity in Patients Undergoing Highly Active Anti-Retroviral Therapy in Two Public Health Facilities in Uganda.
  22. R Magazine,H A Shahul,B Chogtu,A Kamath (2016). Comparison of oral montelukast with oral zileuton in acute asthma: A randomized, double-blind, placebo-controlled study.
  23. D Lal,S Manocha,Ray Vijayan V K,R Kumar (2015). Comparative study of the efficacy and safety of the ophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease.
  24. H B Lande,S Kamble,M Pawar,S C Mohapatra (2016). Newer initiatives under rntcp.
  25. S Najafi (2018). Importance of Pharmacovigilance and the Role of Healthcare Professionals.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Saurabh Nimesh. 2020. \u201cPharmacovigilance Programme of India: A Review\u201d. Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine GJMR-B Volume 19 (GJMR Volume 19 Issue B3).

Download Citation

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-B Classification NLMC Code: QV 20.5
Version of record

v1.2

Issue date
January 8, 2020

Language
en
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 2510
Total Downloads: 1306
2026 Trends
Related Research
Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Pharmacovigilance Programme of India: A Review

Saurabh Nimesh
Saurabh Nimesh <p>Dr. A.P.J. Abdul Kalam Technical University</p>
Surabhi Gupta
Surabhi Gupta
Kapil Dev Negi
Kapil Dev Negi

Research Journals